ANTIBODIES CAPABLE OF BINDING HLA-A2/TYRD IN AN HLA RESTRICTED MANNER AND USES THEREOF

Reut Erel Segal; Ravit Oren; Dror Shmuel Alishekevitz; Orit Foord; Aya Jakobovits; Orit Foord; Daulet Kadyl Satpayev; Mira Peled Kamar; Galit Denkberg; Yoram Reiter; Ilan Beer; Keren Sinik; Yael Teboul (Elbaz); Yael Shperber (Sery)

ANTIBODIES CAPABLE OF BINDING HLA-A2/TYRD IN AN HLA RESTRICTED MANNER AND USES THEREOF

Reut Erel Segal (Inventor), Ravit Oren (Inventor), Dror Shmuel Alishekevitz (Inventor), Orit Foord (Inventor), Aya Jakobovits (Inventor), Orit Foord (Inventor), Daulet Kadyl Satpayev (Inventor), Mira Peled Kamar (Inventor), Galit Denkberg (Inventor), Yoram Reiter (Inventor), Ilan Beer (Inventor), Keren Sinik (Inventor), Yael Teboul (Elbaz) (Inventor), Yael Shperber (Sery) (Inventor)

Technion - Israel Institute of Technology

Research output: Patent

Abstract

Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.

Original language	American English
Patent number	US2020207858 AA
IPC	C07K 16/ 28 A I
Priority date	14/06/17
State	Published - 2 Jul 2020

Cite this

@misc{d84299763c0242e89da3cbe0147c114d,

title = "ANTIBODIES CAPABLE OF BINDING HLA-A2/TYRD IN AN HLA RESTRICTED MANNER AND USES THEREOF",

abstract = "Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.",

author = "{Erel Segal}, Reut and Ravit Oren and Alishekevitz, {Dror Shmuel} and Orit Foord and Aya Jakobovits and Orit Foord and Satpayev, {Daulet Kadyl} and {Peled Kamar}, Mira and Galit Denkberg and Yoram Reiter and Ilan Beer and Keren Sinik and {Teboul (Elbaz)}, Yael and {Shperber (Sery)}, Yael",

year = "2020",

month = jul,

day = "2",

language = "American English",

type = "Patent",

note = "US2020207858 AA; C07K 16/ 28 A I",

}

TY - PAT

T1 - ANTIBODIES CAPABLE OF BINDING HLA-A2/TYRD IN AN HLA RESTRICTED MANNER AND USES THEREOF

AU - Erel Segal, Reut

AU - Oren, Ravit

AU - Alishekevitz, Dror Shmuel

AU - Foord, Orit

AU - Jakobovits, Aya

AU - Foord, Orit

AU - Satpayev, Daulet Kadyl

AU - Peled Kamar, Mira

AU - Denkberg, Galit

AU - Reiter, Yoram

AU - Beer, Ilan

AU - Sinik, Keren

AU - Teboul (Elbaz), Yael

AU - Shperber (Sery), Yael

PY - 2020/7/2

Y1 - 2020/7/2

N2 - Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.

AB - Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.

M3 - Patent

M1 - US2020207858 AA

ER -

ANTIBODIES CAPABLE OF BINDING HLA-A2/TYRD IN AN HLA RESTRICTED MANNER AND USES THEREOF

Abstract

Fingerprint

Cite this